Psychiatry Consortium

The Psychiatry Consortium will focus on identifying and validating novel drug targets for behavioural symptoms affecting people with mental health conditions and dementia.

Amount:

Supported by the Wellcome Trust collectively, the Psychiatry Consortium partners will aim to provide £3 million in research funding over a period of 3 years.

The Psychiatry Consortium is a private-charity partnership between Alzheimer’s Research UK, Medicines Discovery Catapult and MQ: Transforming mental health. The major industry players engaged as founding members of the consortium include: Biogen, Boehringer Ingelheim, Johnson & Johnson Innovation Limited, Lundbeck, MSD and Takeda.

  • Engage the psychiatry academic community globally by providing opportunities for funding, collaboration & access to industry and commercialisation know-how
  • Identify novel therapeutic targets and strategies to treat psychiatric diseases
  • Increase the number of new targets and screening assays, validated to industry standards, to support the discovery and development of new drugs

Supported by the Wellcome Trust collectively, the Psychiatry Consortium partners will aim to provide £3 million in research funding over a period of 3 years.

The aim of the Psychiatry Consortium is to deliver up to 10 high-value drug discovery projects.

The consortium will begin work on early drug discovery projects to target psychiatric symptoms. The projects funded will focus of new biological targets emerging from:

  • mechanism of actions studies
  • genetics hits
  • disease driven hypothesis

For more information about the Consortium and the application process visit the Psychiatry Consortium website.

Next deadline: 22 November 2019. Apply here.

To view other funding opportunities through Alzheimer’s Research UK in drug discovery visit our website here.

Download our GDPR statement that explains how Alzheimer’s Research UK Research Team handles personal data about our grant applications and the rights that applicants have under data protection law. In this Notice, we refer to this type of information as “Applicant Data”.

Download GDPR statement

Download our Bullying and Harassment policy that explains how Alzheimer’s Research UK Research Team handles allegations of bullying or harassment involving any of our grant participants.

Download Bullying and Harassment policy

These statements apply to applications submitted via Grant Tracker. They also apply to applications summitted via other means, such as by post and email.